Biocept Inc BIOC Fundamentals and Key Ratios

Biocept Inc. (BIOC) Fundamentals


Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

SHARE INFORMATION
Market Cap	$ 5,288,219
Shares Outstanding	17,058,770
Float	17,053,629
Percent Float	99.97%
Short Interest	0.00
Short Percent Float	0.0%
Short Interest Ratio	0.00
Short Interest Date	-
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 61,248,999
Latest Fiscal EPS	$ -0.19
Latest Fiscal Date	2021-12-31

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	56
Institutional Holdings Date	2023-02-28
Institutional Bought Previous 3 Months	451
Institutional Holdings Percent	18.3%
Institutional Sold Previous 3 Months	64,834
Insider Holdings Date	2023-02-28
Insider Bought Previous 3 Months	-
Insider Holdings Percent	3.0
Insider Sold Previous 3 Months	-
Insider Shares Owned	520,177

TRADING INFO
52 Week High	$ 2.43
52 Week Low	$ 0.24
52 Week High Change	$ -85.97
21 Day Moving Average	$ 0.3863
21 Day Extended Moving Average	$ 0.370589
50 Day Moving Average	$ 0.4759
50 Day Extended Moving Average	$ 0.454975
200 Day Moving Average	$ 0.765743
200 Day Extended Moving Average	$ 0.92645
10 Day Average Volume	211,970
20 Day Average Volume	153,026
30 Day Average Volume	121,865
50 Day Average Volume	106,747
Alpha	-0.045217
Beta	1.0068
Standard Deviation	0.347949
R2	0.024281
7 Day Price Change	$ -0.0169
7 Day Percent Change	-5.17%
21 Day Price Change	$ -0.1508
21 Day Percent Change	-32.73%
30 Day Price Change	$ -0.211
30 Day Percent Change	-40.5%
Month to Date Price Change	$ -0.211
Month to Date Percent Change	-40.5%
Quarter to Date Price Change	$ -0.22
Quarter to Date Percent Change	-41.51%
180 Day Price Change	$ -0.5901
180 Day Percent Change	-65.56%
200 Day Price Change	$ -0.6031
200 Day Percent Change	-66.05%
Year to Date Price Change	$ -0.22
Year to Date Percent Change	-41.51%

PROFITABILITY
EBIT Margin	-32.1%
EBITDA Margin	-26.5%
Pre-Tax Profit Margin	-251.2%
Profit Margin Count	-37.53%
Gross Margin	31.8%
Profit Margin TOT	-37.53%

INCOME STATEMENTS
Revenue	$ 36,143,000
Revenue Per Share	$ 2.1187
Revenue (3 Years)	$ 95.93
Revenue (5 Years)	$ 73.04

FINANCIAL STRENGTH
Price to Tangible Book	0.20
Total Debt To Equity	0.50
Int Coverage	-47.40
Current Ratio	5.10
Leverage Ratio	1.80
Quick Ratio	4.70
Long Term Debt To Capital	0.27

VALUATION MEASURES
PE Ratio	6.40
Enterprise Value	$ -777,840
Price to Sales	0.146314
Price to Free Cash	-0.50
PE High Last 5 Years	-0.40
Price To Book	0.20
Price To Cash Flow	6.70
PE Low Last 5 Years	-1.90
Price to Tangible Book	0.20

MANAGEMENT EFFECTIVENESS
Receivables Turnover	2.60
Invoice Turnover	16.30
Assets Turnover	0.70
Return Assets	-31.93
Return on Equity	-53.82
Return on Capital	-35.10

PROFILE INFO
Issue Type	CS
SEC Type	EQS
Auditor	Mayer Hoffman McCann P.C.
CEO	Samuel D. Riccitelli
Emplyoees	192
Last Audit	UQ
CIK	0001044378
Industry	Medical Diagnostics & Research
Sector	Healthcare
NAICS	Medical Laboratories(621511)

CONTACT INFO
Address	9955 Mesa Rim Road Suite 150 San Diego, CA 92121
Website	https://www.biocept.com
Facsimile	+1 858 320-8225
Telephone	+1 858 320-8200
Email	ir@biocept.com

Boards:

Quotes:

BIOC